Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology
28 juil. 2021 08h00 HE | ARCA biopharma, Inc.
Analysis in full patient cohort shows Gencaro effect compared to standard of careIn the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with...
CVRx Logo_R_RGB_black.png
CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call
21 juil. 2021 17h28 HE | CVRx, Inc.
MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors
12 juil. 2021 08h00 HE | CVRx, Inc.
MINNEAPOLIS, July 12, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally...
CVRx Logo_R_RGB_black.png
CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
02 juil. 2021 16h05 HE | CVRx, Inc.
MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx Logo_R_RGB_black.png
CVRx, Inc. Announces Upsized Pricing of Initial Public Offering
29 juin 2021 20h17 HE | CVRx, Inc.
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
CVRx Logo_R_RGB_black.png
CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
10 juin 2021 11h19 HE | CVRx, Inc.
MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
Caregiver Action Network Announces New Resource for Families of Loved Ones with Heart Failure
08 juin 2021 13h46 HE | Caregiver Action Network
Washington, DC, June 08, 2021 (GLOBE NEWSWIRE) -- Hearing that a loved one has been diagnosed with heart failure brings fear, stress, and a whole lot of questions. Caregiver Action Network has...
Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress
22 avr. 2021 16h32 HE | Cardiometabolic Health Congress
Boca Raton, FL, April 22, 2021 (GLOBE NEWSWIRE) -- Clinical Highlights: 2021 CMHC Spring Cardiometabolic Health Congress Top Experts Convene to Discuss the Syndemic of COVID-19 &...
Fierce Medtech Names CVRx as One of its “Fierce 15” Companies
15 mars 2021 10h00 HE | CVRx, Inc.
MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
Berlin.png
BERLIN HEALS Announces results of first-in-human study for its Implantable C-MIC device for the Treatment of Heart Failure with Electrical Microcurrent and the Launch of a pivotal CE Mark Study
04 mars 2021 11h00 HE | Berlin Heals Holding AG
BERLIN and ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- BERLIN HEALS, a company dedicated to developing and offering novel and life-saving treatments for patients suffering from heart...